Senti Biosciences Holdings (SNTI) Other Accumulated Expenses (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Other Accumulated Expenses of $73000.0 for Q4 2025, down 83.14% year-over-year from $433000.0 in Q4 2024, and up 17.74% quarter-over-quarter from $62000.0 in Q3 2025.
Senti Biosciences Holdings (SNTI) Other Accumulated Expenses (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $73000.0 for Q4 2025.
- In Q4 2025, Other Accumulated Expenses fell 83.14% year-over-year to $73000.0; the TTM figure through Dec 2025 stood at $73000.0 (down 83.14% YoY), while the FY2025 annual figure was $73000.0, down 83.14% from the prior year.
- Other Accumulated Expenses for Q4 2025 stood at $73000.0, up from $62000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $433000.0 in Q4 2024, with the low at $3000.0 in Q1 2024.
- The 5-year median for Other Accumulated Expenses is $53000.0 (2023), against an average of $93250.0.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses slumped 94.34% in 2024, then soared 13933.33% in 2025.
- Senti Biosciences Holdings' Other Accumulated Expenses stood at $111000.0 in 2021, then tumbled by 73.87% to $29000.0 in 2022, then sank by 68.97% to $9000.0 in 2023, then jumped by 4711.11% to $433000.0 in 2024, then slumped by 83.14% to $73000.0 in 2025.
- Business Quant data shows SNTI's Other Accumulated Expenses at $73000.0 in Q4 2025, $62000.0 in Q3 2025, and $53000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 73,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | 421,000.00 |
| Dec 31, 2024 | 433,000.00 |
| Sep 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 76,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | 22,000.00 |
| Jun 30, 2023 | 32,000.00 |
| Mar 31, 2023 | 53,000.00 |
| Dec 31, 2022 | 29,000.00 |
| Sep 30, 2022 | 54,000.00 |
| Jun 30, 2022 | 23,000.00 |
| Dec 31, 2021 | 111,000.00 |